Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002045027-25-000003
Filing Date
2025-12-04
Accepted
2025-12-04 16:50:45
Documents
1
Period of Report
2025-12-02

Document Format Files

Seq Description Document Type Size
1 form4-12042025_091242.html 4  
1 form4-12042025_091242.xml 4 5837
  Complete submission text file 0002045027-25-000003.txt   7271
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Issuer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ACLARIS THERAPEUTICS, INC. 701 LEE ROAD, SUITE 103 WAYNE PA 19087
Business Address
Davis Hugh M. (Reporting) CIK: 0002045027 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37581 | Film No.: 251550388